AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL RESULTS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Amgen (AMGN) Q4 earnings and revenue beat estimates
February 6, 2024 4:14 PM ESTAmgen (NASDAQ: AMGN) posted better-than-expected fourth-quarter earnings and revenue.
The biopharma company reported Q4 earnings per share (EPS) of $4.71, topping the consensus projection of $4.59. It generated $8.2 billion in revenue during the quarter, up 20% year-over-year, and above the estimated $8.12 billion.
Product sales brought in... More
Amgen (AMGN) Tops Q4 EPS by 12c, Offers Guidance
February 6, 2024 4:03 PM ESTAmgen (NASDAQ: AMGN) reported Q4 EPS of $4.71, $0.12 better than the analyst estimate of $4.59. Revenue for the quarter came in at $8.2 billion versus the consensus estimate of $8.12 billion.
GUIDANCE:
Amgen sees FY2024 EPS of $18.90-$20.30, versus the consensus of $19.83. Amgen sees... More
